# The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation

Study · id `cardio:ct-nct07925359` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07925359](<https://clinicaltrials.gov/study/NCT07925359>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07925359

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07925359. Allocation not applicable; no masking; primary purpose treatment. Start 2027-01-20 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07925359, source copy `cardio:ctgov-nct07925359-2026-11-09`, retrieved 2026-11-18)
- Planned start: 2027-01-20 (anticipated) (ClinicalTrials.gov record NCT07925359, source copy `cardio:ctgov-nct07925359-2026-11-09`, retrieved 2026-11-18)
- Primary completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07925359, source copy `cardio:ctgov-nct07925359-2026-11-09`, retrieved 2026-11-18)
- Completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07925359, source copy `cardio:ctgov-nct07925359-2026-11-09`, retrieved 2026-11-18)
- Countries: Croatia; Czechia; France (ClinicalTrials.gov record NCT07925359, source copy `cardio:ctgov-nct07925359-2026-11-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07925359-2026-11-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial Fibrillation
- Acronym: NAVigate-ULTRA
- Condition: Atrial Fibrillation (AF)
- Condition: Paroxysmal AF
- Condition: Persistent Atrial Fibrillation (PersAF)
- Condition: FARAPULSE
- Intervention (Device): Ablation Treatment with FARAPULSE™ Pulsed Field Ablation (PFA) System and OPAL HDx™ Mapping System
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: abb3ce7cc3922f6ccbca921c089f2dd937390d116eea5c322b564c870c4cc3a8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
